Statement on human papillomavirus DNA test utilization.

Department of Health and Human Services, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, Rockville, MD 20852, USA. ds87v
Archives of pathology & laboratory medicine (Impact Factor: 2.84). 09/2009; 133(8):1276-7. DOI: 10.1043/1543-2165-133.8.1276
Source: PubMed
Download full-text


Available from: Diane Davis Davey, Jan 15, 2014
5 Reads
  • Source
    • "HC2 could become cost-effective only in situations where referral to colposcopy and further management are very expensive and the triage test is very cheap, leading to savings by a small reduction of colposcopy referrals. Currently, in Europe and the USA, HPV triage of MD/LSIL is not considered costeffective and referral to colposcopy or repeat cytology are recommended options (Solomon et al, 2009; Jordan et al, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.
    British Journal of Cancer 09/2011; 105(7):877-80. DOI:10.1038/bjc.2011.351 · 4.84 Impact Factor
  • Source
    Cancer 06/2009; 117(3):149-50. DOI:10.1002/cncy.20030 · 4.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.
    Clinical & Experimental Immunology 11/2010; 163(1):17-25. DOI:10.1111/j.1365-2249.2010.04268.x · 3.04 Impact Factor
Show more